Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity

Bironzo, Paolo;
2017-01-01

2017
103
5
405
421
http://www.tumorijournal.com/Attach/2bd97cf7-0a99-438a-9ffe-e0c913347c6c/e796b3c6-5272-4ef3-8a34-e7dfa9bcf5ee
Immune checkpoint inhibitors; Immune-related adverse events; Toxicity; Antibodies, Monoclonal; Antineoplastic Agents; CTLA-4 Antigen; Cell Cycle Checkpoints; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Programmed Cell Death 1 Receptor; Treatment Outcome; Oncology; Cancer Research
Inno, Alessandro; Metro, Giulio; Bironzo, Paolo; Grimaldi, Antonio M; Grego, Elisabetta; Nunno, Vincenzo Di; Picasso, Virginia; Massari, Francesco; Go...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1692396
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 46
social impact